Tilray Brands Inc

TLRY

7.580USD

+0.530+7.52%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Tilray Brands Inc's Score

Industry at a Glance

Industry Ranking

97 / 159

Overall Ranking

262 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Tilray Brands Inc Highlights

StrengthsRisks

Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 30.96% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 821.31M.

Overvalued

The company’s latest PE is -0.32, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 13.73M shares, decreasing 3.15% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 411.08K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.62.

Analyst Rating

Based on 11 analysts

Hold

Current Rating

12.394

Target Price

+75.81%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Tilray Brands Inc is 7.66, ranking 104 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 217.51M, representing a year-over-year increase of 3.11%, while its net profit experienced a year-over-year increase of 47.35%.

Score

Industry at a Glance

Previous score

7.66

Change

0



Financials

7.96

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.06

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.96

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.30

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Tilray Brands Inc is 8.58, ranking 13 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -0.32, which is -54.57% below the recent high of -0.15 and -1968.73% above the recent low of -6.68.

Score

Industry at a Glance

Previous score

8.58

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 97/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Tilray Brands Inc is 6.36, ranking 131 out of 159 in the Pharmaceuticals industry. The average price target is 18.00, with a high of 25.00 and a low of 8.50.

Score

Industry at a Glance

Previous score

6.36

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Tilray Brands Inc is 7.02, ranking 84 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 9.48 and the support level at 6.32, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.71

Change

0.31

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Tilray Brands Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 11.79%, representing a quarter-over-quarter increase of 21.57%. The largest institutional shareholder is The Vanguard, holding a total of 411.08K shares, representing 0.35% of shares outstanding, with 15.66% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Tidal Investments LLC

2.61M

-9.81%

HRT Financial LP

1.48M

+1387.83%

Susquehanna International Group, LLP

1.01M

+129.17%

UBS Financial Services, Inc.

227.88K

-0.19%

Millennium Management LLC

494.23K

+280.98%

Simon (Irwin D)

482.65K

--

Jane Street Capital, L.L.C.

441.35K

+85.87%

The Vanguard Group, Inc.

Star Investors

378.48K

-11.16%

RBC Dominion Securities, Inc.

368.00K

+56.87%

Global X Investments Canada Inc.

341.00K

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Tilray Brands Inc is 1.18, ranking 154 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.98. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Tilray Brands Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Tilray Brands Inc

TLRY

6.30 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

9.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Regeneron Pharmaceuticals Inc

REGN

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment